Discuss Prostamax on glp1chat
Join the forum to discuss research with other members.
At a glance
Prostamax is a short peptide studied in experimental prostate inflammation models. Researchers look for changes in tissue appearance and inflammation-related markers; those are the effects measured in these models.
Researchers use prostate-inflammation models to see whether tissue appearance and inflammatory markers change after exposure to this short peptide. The proposed mechanism involves changing which cellular instructions are active during stress. Those are measurable early signals, not a direct measure of easier urination, less pain or disease control in a patient. The specific experimental model matters when interpreting the name.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses experimental prostatitis and tissue-marker findings. Animal changes in histology do not demonstrate symptom improvement or disease treatment in people.[1][2][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Prostamax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (2 mL = 10 mg/mL)
| Phase / Week | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Route: Intramuscular (IM) injection once daily[1][2] Frequency: Inject once daily intramuscularly. Preclinical studies used daily IM administration for 15–60 days[1][2]. For administrations ≤10 units (≤0.10 mL), consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support prostate tissue health and function through bioregulatory peptide signaling[1][2].
- Schedule: Daily intramuscular injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500 mcg–1 mg daily with gradual titration.
- Reconstitution: 2.0 mL per 20 mg vial (10 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 2 weeks.
Suggested daily titration approach.
- Start: 500 mcg (0.5 mg) daily; increase by ~250 mcg every 2 weeks as tolerated.
- Target: 1 mg daily by Weeks 5–8.
- Frequency: Once per day (intramuscular).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites among large muscle groups.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2 weeks.
Storage Instructions
Proper storage preserves peptide quality[7].
- Lyophilized (short‑term): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
- Lyophilized (long‑term): Store at −20 °C (−4 °F) for extended stability.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~2 weeks and avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
Intramuscular administration guidance from clinical best‑practice resources[5][9].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- For IM injection, use a 22–25 gauge, 1–1.5 inch needle inserted at 90° into a large muscle (deltoid, vastus lateralis, or gluteus)[5].
- Aspiration before IM injection is no longer routinely recommended for most sites[6].
- Inject slowly and steadily; wait briefly before withdrawing.
- Rotate sites systematically to avoid muscle irritation or fibrosis[8].
- Alternative (SC): If subcutaneous route is preferred, use a 23–25 gauge, 5/8 inch needle at 45° into fatty tissue[5].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Prostamax, 20 mg each):
- 8 weeks ≈ 2 vials (~40 mg total at ~0.7 mg/day average)
- 12 weeks ≈ 3 vials (~60 mg total)
- 16 weeks ≈ 4 vials (~80 mg total at ~1 mg/day maintenance)
-
Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (4 vials): 8 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 05
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
CDC — Vaccine administration: During vaccination (aspiration guidance, aseptic technique) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — General best practices for immunization: injection technique and safety (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.